{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T03:40:06Z","timestamp":1743910806573,"version":"3.40.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2025-A-013"],"award-info":[{"award-number":["CSH-2025-A-013"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04213-y","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:55:22Z","timestamp":1743893722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013glucose cotransporter 2 inhibitors and bullous pemphigoid risk in US and global population: real world evidences"],"prefix":"10.1007","volume":"317","author":[{"given":"Hui-Chin","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsu-Man","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Sheng","family":"Jhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiu-Jau","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Che","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo-Yan","family":"Gau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"4213_CR1","doi-asserted-by":"publisher","first-page":"1088083","DOI":"10.3389\/fmed.2022.1088083","volume":"9","author":"SC Huang","year":"2022","unstructured":"Huang SC, Chiu TM, Lee CY, Chang HC, Wu WJ, Gau SY (2022) Researching trends in pemphigoid diseases: A bibliometric study of the top 100 most cited publications. Front Med (Lausanne) 9:1088083","journal-title":"Front Med (Lausanne)"},{"key":"4213_CR2","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.7150\/ijms.55421","volume":"18","author":"L Huang","year":"2021","unstructured":"Huang L, Liu Y, Li H, Huang W, Geng R, Tang Z et al (2021) Bullous pemphigoid and diabetes medications: A disproportionality analysis based on the FDA adverse event reporting system. Int J Med Sci 18:1946\u20131952","journal-title":"Int J Med Sci"},{"key":"4213_CR3","doi-asserted-by":"crossref","unstructured":"Ujiie I, Katayama S, Mai Y, Mai S, Yoshimoto N, Muramatsu K et al (2024) Clinical characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid patients: A retrospective study. J Am Acad Dermatol","DOI":"10.1016\/j.jaad.2024.09.067"},{"key":"4213_CR4","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/jdv.18106","volume":"36","author":"SH Ma","year":"2022","unstructured":"Ma SH, Wu CY, Lyu YS, Chou YJ, Chang YT, Wu CY (2022) Association between sodium-glucose co-transporter 2 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a nationwide population-based cohort study. J Eur Acad Dermatology Venereology: JEADV 36:1318\u20131324","journal-title":"J Eur Acad Dermatology Venereology: JEADV"},{"key":"4213_CR5","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.jid.2021.05.015","volume":"141","author":"O Varpuluoma","year":"2021","unstructured":"Varpuluoma O, Jokelainen J, Huilaja L, Tasanen K (2021) GLP-1 analogs and SGLT2 inhibitors do not increase risk of bullous pemphigoid. J Invest Dermatol 141:2969\u20132972e2961","journal-title":"J Invest Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04213-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04213-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04213-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T03:22:43Z","timestamp":1743909763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04213-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4213"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04213-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TriNetX database was previously approved by the Western Institutional Review Board (Western IRB). The subsequent determination regarding the de-identification process attested on December 2020 replaced the need of Western IRB approval in TriNetX studies. Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants\u2019 legal guardians\/next of kin in accordance with the national legislation and the institutional requirements. This retrospective study is exempt from informed consent. The data reviewed is a secondary analysis of existing data, does not involve intervention or interaction with human subjects, and is de-identified per the de-identification standard defined in Sect.\u00a0164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Sect.\u00a0164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Data in this study were retrieved from TriNetX Research Network. All data available in the database were administrated by the TriNetX platform. Detailed information can be retrieved at the official website of the research network ().","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availablity"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"675"}}